Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

Rosemary Sutton; Luciano Dalla Pozza; Seong Lin Khaw; Chris Fraser; Tom Revesz; Janis Chamberlain; Richard Mitchell; Toby N. Trahair; Caroline M. Bateman; Nicola C. Venn; Tamara Law; Erika Ong; Susan L. Heatley; Barbara J. McClure; Claus Meyer; Rolf Marschalek; Michelle J. Henderson; Siobhan Cross; Deborah L. White; Rishi S. Kotecha

doi:10.1002/pbc.28922

Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

Rosemary Sutton, Luciano Dalla Pozza, Seong Lin Khaw, Chris Fraser, Tom Revesz, Janis Chamberlain, Richard Mitchell, Toby N. Trahair, Caroline M. Bateman, Nicola C. Venn, Tamara Law, Erika Ong, Susan L. Heatley, Barbara J. McClure, Claus Meyer, Rolf Marschalek, Michelle J. Henderson, Siobhan Cross, Deborah L. White, Rishi S. Kotecha

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.

Original language	English
Article number	e28922
Journal	Pediatric Blood and Cancer
Volume	68
Issue number	5
DOIs	https://doi.org/10.1002/pbc.28922
Publication status	Published or Issued - May 2021

Keywords

acute lymphoblastic leukaemia
blinatumomab
paediatric
refractory
relapse

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.28922

Cite this

Sutton, R., Pozza, L. D., Khaw, S. L., Fraser, C., Revesz, T., Chamberlain, J., Mitchell, R., Trahair, T. N., Bateman, C. M., Venn, N. C., Law, T., Ong, E., Heatley, S. L., McClure, B. J., Meyer, C., Marschalek, R., Henderson, M. J., Cross, S., White, D. L., & Kotecha, R. S. (2021). Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Pediatric Blood and Cancer, 68(5), [e28922]. https://doi.org/10.1002/pbc.28922

@article{f8246b83f7d14a9fa8f2a8c2dc3dd53b,

title = "Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab",

abstract = "We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.",

keywords = "acute lymphoblastic leukaemia, blinatumomab, paediatric, refractory, relapse",

author = "Rosemary Sutton and Pozza, {Luciano Dalla} and Khaw, {Seong Lin} and Chris Fraser and Tom Revesz and Janis Chamberlain and Richard Mitchell and Trahair, {Toby N.} and Bateman, {Caroline M.} and Venn, {Nicola C.} and Tamara Law and Erika Ong and Heatley, {Susan L.} and McClure, {Barbara J.} and Claus Meyer and Rolf Marschalek and Henderson, {Michelle J.} and Siobhan Cross and White, {Deborah L.} and Kotecha, {Rishi S.}",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2021",

month = may,

doi = "10.1002/pbc.28922",

language = "English",

volume = "68",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "5",

}

Sutton, R, Pozza, LD, Khaw, SL, Fraser, C, Revesz, T, Chamberlain, J, Mitchell, R, Trahair, TN, Bateman, CM, Venn, NC, Law, T, Ong, E, Heatley, SL, McClure, BJ, Meyer, C, Marschalek, R, Henderson, MJ, Cross, S, White, DL & Kotecha, RS 2021, 'Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab', Pediatric Blood and Cancer, vol. 68, no. 5, e28922. https://doi.org/10.1002/pbc.28922

TY - JOUR

T1 - Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

AU - Sutton, Rosemary

AU - Pozza, Luciano Dalla

AU - Khaw, Seong Lin

AU - Fraser, Chris

AU - Revesz, Tom

AU - Chamberlain, Janis

AU - Mitchell, Richard

AU - Trahair, Toby N.

AU - Bateman, Caroline M.

AU - Venn, Nicola C.

AU - Law, Tamara

AU - Ong, Erika

AU - Heatley, Susan L.

AU - McClure, Barbara J.

AU - Meyer, Claus

AU - Marschalek, Rolf

AU - Henderson, Michelle J.

AU - Cross, Siobhan

AU - White, Deborah L.

AU - Kotecha, Rishi S.

PY - 2021/5

Y1 - 2021/5

N2 - We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.

AB - We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.

KW - acute lymphoblastic leukaemia

KW - blinatumomab

KW - paediatric

KW - refractory

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=85101855796&partnerID=8YFLogxK

U2 - 10.1002/pbc.28922

DO - 10.1002/pbc.28922

M3 - Article

C2 - 33638292

AN - SCOPUS:85101855796

SN - 1545-5009

VL - 68

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 5

M1 - e28922

ER -

Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this